Document is current
Any future updates will be listed below
-
Authors
Aquilanti, Elisa
Touat, Mehdi
French, Pim https://orcid.org/0000-0002-0668-9529
Iavarone, Antonio https://orcid.org/0000-0002-0683-4634
Capper, David https://orcid.org/0000-0003-1945-497X
Geurts, Marjolein
Rahman, Rifaquat
Verhaak, Roel https://orcid.org/0000-0003-2773-0436
Preusser, Matthias https://orcid.org/0000-0003-3541-2315
van den Bent, Martin https://orcid.org/0000-0001-5710-5127
Wen, Patrick Y. https://orcid.org/0000-0002-0774-7700
- License Information
-
More Information
Article History
Accepted: 20 July 2026
First Online: 19 August 2026
Ethics
Competing interests: M.T. has acted as a consultant or adviser of Bayer, FORE, GSK, Novocure, Resilience, and Servier and has received research funding from Amgen and Sanofi. P.F. has acted as a consultant and speaker for Servier. A.I. owns shares of Immunomica srl. D.C. has received honoraria for lectures and consultancy from Servier, research support from NovoCure, royalties from the sales of the BRAF V600E -mutation-specific antibody VE1 (Ventana, Roche), and is a cofounder and shareholder of Heidelberg Epignostix GmbH. M.G. has acted as a consultant or adviser for or received travel reimbursement from Carthera, Evgen Pharm, MyTomorrows, Nuvation Bio and Servier Medical Affairs. R.R. has acted as a consultant and/or adviser for Servier Pharmaceuticals, St. Lucia Consulting and Telix Pharmaceuticals. R.V. owns equity in Boundless Bio. M.P. has acted as a consultant and/or advisor forAbbVie, AdAcAp, Adastra, AstraZeneca, Bayer, BMJ Journals, Böhringer-Ingelheim, Bristol-Myers Squibb, CMC Contrast, Daiichi Sankyo, Gan & Lee Pharmaceuticals, Gerson Lehrman Group (GLG), GlaxoSmithKline, ITM Oncologics GmbH, Lilly, Medac, Medahead, MedMedia, Medscape, Merck Sharp & Dome, Miltenyi, Mundipharma, Nerviano Medical Sciences, Novartis, OncLive, Roche, Sanofi, Servier, Telix and TocagenJanssen. M.v-d.B. has received honoraria from AstraZeneca, Boehringer, Chimerix, Fore Biotherapeutics, Genenta, Incyte, Nuvation, and Servier and has received research support from Boehringer and travel support from Servier. P.Y.W. has acted as a consultant and/or advisor for Alexion/AstraZeneca, Black Diamond, Chimerix, Day One Bio, Fore Biotherapeutics, Genenta, Glaxo Smith Kline, Imvax, Kintara, Merck, Mundipharma, Nerviano, Nuvation Bio, Novartis, Novocure, Nuvation Bio, Medical Sciences, Rigel, Sapience, Servier, and Telix and research support from AstraZeneca, Black Diamond, Bristol Meyers Squibb, Chimerix, Eli Lily, Erasca, Global Coalition For Adaptive Research, MediciNova, Merck, Nerviano, Novartis, Philogen, Quadriga, Servier. E.A. declares no competing interests.
